GABY Past Earnings Performance
Past criteria checks 0/6
GABY's earnings have been declining at an average annual rate of -26.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 51% per year.
Key information
-26.4%
Earnings growth rate
27.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 51.0% |
| Return on equity | n/a |
| Net Margin | -154.7% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How GABY makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 21 | -32 | 10 | 0 |
| 31 Dec 22 | 22 | -29 | 10 | 0 |
| 30 Sep 22 | 21 | -8 | 10 | 0 |
| 30 Jun 22 | 24 | -8 | 11 | 0 |
| 31 Mar 22 | 29 | -6 | 11 | 0 |
| 31 Dec 21 | 26 | -10 | 10 | 0 |
| 30 Sep 21 | 20 | -12 | 8 | 0 |
| 30 Jun 21 | 13 | -10 | 7 | 0 |
| 31 Mar 21 | 5 | -10 | 5 | 0 |
| 31 Dec 20 | 3 | -10 | 6 | 0 |
| 30 Sep 20 | 4 | -14 | 7 | 0 |
| 30 Jun 20 | 7 | -14 | 8 | 0 |
| 31 Mar 20 | 8 | -15 | 9 | 0 |
| 31 Dec 19 | 8 | -15 | 9 | 0 |
| 30 Sep 19 | 6 | -8 | 8 | 0 |
| 30 Jun 19 | 2 | -8 | 7 | 0 |
| 31 Mar 19 | 1 | -6 | 5 | 0 |
| 31 Dec 18 | 1 | -6 | 4 | 0 |
| 30 Sep 18 | 1 | -5 | 3 | 0 |
| 30 Jun 18 | 1 | -4 | 3 | 0 |
| 31 Mar 18 | 1 | -3 | 2 | 0 |
| 31 Dec 17 | 1 | -3 | 2 | 0 |
| 31 Dec 16 | 0 | -2 | 2 | 0 |
| 31 Dec 15 | 0 | -2 | 2 | 0 |
Quality Earnings: GABY is currently unprofitable.
Growing Profit Margin: GABY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GABY is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare GABY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GABY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: GABY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.